GLA
CYTK icon

Great Lakes Advisors’s Cytokinetics CYTK Stock Holding History

Great Lakes Advisors’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.96M Sell
23,002
-1,979
-8% -$142K 0.01% 429
2026
Q1 		$1.65M Sell
24,981
-36
-0.1% -$2.29K 0.01% 454
2025
Q4 		$1.59M Buy
25,017
+144
+0.6% +$8.96K 0.01% 462
2025
Q3 		$1.37M Sell
24,873
-7,856
-24% -$324K 0.01% 495
2025
Q2 		$1.08M Sell
32,729
-1,097
-3% -$38.2K 0.01% 507
2025
Q1 		$1.36M Buy
33,826
+237
+0.7% +$10.9K 0.01% 483
2024
Q4 		$1.58M Buy
+33,589
New +$1.74M 0.01% 511

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Great Lakes Advisors's CYTK Position: Q2 2026 in Review

Great Lakes Advisors reduced its Cytokinetics (CYTK) stake by 7.9% in Q2 2026, selling an estimated $142K and leaving 23,002 shares worth $1.96M. The position accounts for 0.01% of the portfolio, ranked #429.

Great Lakes Advisors first reported a position in CYTK in Q4 2024 and has held it in 7 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Great Lakes Advisors held 23,002 shares of Cytokinetics worth $1.96M as of Q2 2026.
  • Great Lakes Advisors sold 1,979 Cytokinetics shares in Q2 2026, an estimated $142K.
  • Cytokinetics made up 0.01% of Great Lakes Advisors's portfolio in Q2 2026, its #429 holding.
  • Great Lakes Advisors first reported a position in Cytokinetics in Q4 2024 and has held it in 7 quarters since.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Great Lakes Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.